[1] O EDLING. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 275 2: 854-863.
[2] RYAN T. CAMERON . Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)[J]. Biochemical pharmacology, 2013, 85 9: Pages 1297-1305. DOI:
10.1016/j.bcp.2013.02.026[3] C GROHÉ. Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth.[J]. Journal of Hypertension, 1998, 16 3: 377-384. DOI:
10.1097/00004872-199816030-00015[4] VAN EICKELS MARTIN. The influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats[J]. European Journal of Heart Failure, 2005, 7 7: 1079-1084. DOI:
10.1016/j.ejheart.2005.03.004 
